How to Get Into Biotech Venture Capital: Paths, Pay, and a Plan

To get into biotech venture capital you typically need two things most tech VC candidates do not: enough scientific depth to judge whether a drug or platform can work, and enough financial fluency to judge whether a company built around it can return a fund. Most junior hires arrive with a PhD or MD plus a stint in consulting, banking, equity research, or a startup.

A smaller group comes from healthcare investment banking or life science consulting without a doctorate.

Here's how we see it: the credential gets you considered, and the track record gets you hired. The most dependable route we know of is to build a diligence record before you apply, through fellowships, scout programs, or structured training. Life science funds tend to hire people who have already shown they can evaluate a program.

What biotech venture capital is, and how it differs from tech VC

Biotech VC funds invest in companies developing therapeutics, diagnostics, tools, and increasingly AI-driven discovery platforms. The big difference from software is where value gets created. A software company proves itself with revenue. A therapeutics company proves itself with data readouts and regulatory decisions, and the clinic sets that calendar, not the team.

The FDA's own description of the drug development process puts Phase 1 at 20 to 100 participants over several months, Phase 2 at up to several hundred participants over several months to two years, and Phase 3 at 300 to 3,000 participants over one to four years, with an Investigational New Drug application required before any of it starts. That's the schedule a biotech investor underwrites.

Three structural differences follow:

Milestone-based, tranched financings. A round may be committed in full but released in tranches as preclinical, IND-enabling, and clinical milestones are hit. So diligence tends to price the next data readout rather than the next quarter.
Long holds and staged capital. Approval sits many trial years away, so funds plan for a longer path to exit than in software and reserve heavily for follow-ons. Exits often come through acquisition or an IPO that happens well before revenue.
Company creation is common. Firms build companies in-house around a scientific hypothesis and then hire the team. Flagship Pioneering, for example, trains its Fellows in its own process for generating and refining venture hypotheses, and several other life science firms run in-house incubators.

The market is also concentrating. PitchBook data reported by BioSpace in February 2026 put biopharma venture funding at about $33.8 billion across 1,171 deals in 2025, with just 32 percent of the venture share going to early-stage startups, down from over 40 percent in the 2020 to 2022 period. The median deal size rose to $26.6 million from $19.9 million in 2024.

Fewer, larger checks. That can mean fewer seats, but more diligence per deal, and diligence is the skill we think is most worth showing off.

Who gets into biotech venture capital

Life science funds tend to draw from four pools, each with a recognizable way in. The mix differs from the operator-heavy pipeline into fintech venture capital.

Scientists (PhD or MD). The largest pool at early-stage and company-creation firms. MIT's Communication Lab, in a 2021 write-up of interviews with life science VC professionals, reports that the majority of its interviewees earned a PhD, that several then took a summer fellowship at a venture firm, most commonly an entrepreneurial firm such as Flagship Pioneering, and that joining a biotech startup after graduation was a common next step. It's careful to add that the only conventional thing about getting into VC is that it is unconventional. Published research helps, and so does a domain (oncology, immunology, neuroscience, genetic medicine) that maps to the fund's thesis.

Physicians. MDs are often prized for clinical judgment: reading trial design, understanding endpoints, and knowing how a drug would actually be used. Many combine residency with an MBA or a consulting stint before moving into venture.

Finance and consulting. Healthcare investment bankers, equity research analysts covering biotech, and life science strategy consultants tend to land at later-stage and crossover funds, where modeling and public-market comps matter more than bench science.

Operators and founders. Former CSOs, heads of business development, and exited founders enter at principal or partner level, usually at firms where they already have relationships.

"Without a PhD, don't bother"

You'll hear this, and it isn't baseless. At early-stage and company-creation firms, the doctorate is the norm, and a partner can tell in five minutes whether you can read a figure.

But.

The later-stage and crossover side of the market hires bankers, analysts and consultants without doctorates. And even at science-first firms, a candidate who has written three sharp memos often gets further than one who has only a credential. The degree is a strong signal. It isn't the only one.

What biotech VC pays

At junior levels, pay tends to follow the general venture scale rather than carry a biotech premium. Venture5's 2025 Venture Capital Salary Survey, covering 700+ professionals at 50+ firms, reports median base salaries of $130,000 for associates, $150,000 for senior associates, $200,000 for VPs and principals, and $300,000 for investment partners. Those are base figures only; the survey gives no bonus amounts or carry figures by role.

Mergers & Inquisitions' biotech VC guide puts total associate compensation at roughly $150,000 to $250,000 and says it progresses to the $500,000 to $1 million level at senior levels, with general partners earning more once carried interest pays. Our venture capital salary guide breaks the ladder down by level.

How to get into biotech venture capital: one 12-month plan

Months 1 to 2: pick a lane and a thesis. Decide whether you fit early-stage science (PhD, MD, company creation) or later-stage finance (banking, consulting, crossover). Then write a two-page thesis on one therapeutic area or platform technology: the unmet need, the mechanisms in development, the companies working on them, and what you think the market misunderstands. This becomes your calling card. We like the idea of doing the job before anyone gives you permission, and a thesis is the cheapest way to start.

Months 2 to 4: build a scientific diligence artifact. Take one private company or one recently announced financing and write a mock investment memo: mechanism and the strength of the preclinical package, competitive landscape by mechanism rather than by company, clinical path and endpoints, regulatory strategy, capital needed to the next value inflection, and a probability-weighted return.

Anchor the risk section in real data. Wong, Siah and Lo, writing in Biostatistics in 2019 on trials from 2000 to 2015, estimated an overall probability of success from Phase 1 to approval of 13.8 percent, with transition rates of 66.4 percent from Phase 1 to Phase 2, 48.6 percent from Phase 2 to Phase 3, and 59.0 percent from Phase 3 to approval. Candidates who can weight a program by those odds, and who know which tranche of a financing is released at which milestone, tend to stand out. The venture capital due diligence guide covers the general framework you're adapting.

Months 3 to 6: apply to fellowships and firm programs. Flagship Pioneering runs a paid 12-week summer Fellows program for people who have completed, or are in the final year of, a PhD, MD, or international equivalent, built around its venture creation process; as of September 2026 its page lists information sessions for the 2027 fellowship. Some life science funds also run summer associate or informal scout programs that aren't advertised, so it's worth asking directly. Our guide to the venture capital fellowship landscape lists more.

Months 4 to 9: build a sourcing network in the lab ecosystem. Biotech deal flow tends to come from academic labs, technology transfer offices, and scientific founders, not launch platforms. Nucleate's Activator, an equity-free program that takes no equity from the academic life science teams it supports and ends in a demo day, is one place to meet those founders early; deadlines vary by chapter. You can also help a lab evaluate a licensing opportunity, meet pharma business development people, and track the early companies you meet with your take on each. Sourcing is most of the job, so start hunting early.

Months 6 to 12: run a targeted search. Biotech VC roles are rarely posted widely. A common approach: map 30 to 50 firms by stage and therapeutic focus, find the partner whose portfolio matches your thesis, and send a short note with your memo attached. The get a job in venture capital guide covers outreach, and the venture capital interview questions guide covers what to expect once you're in the room.

How to get into biotech venture capital: what hiring managers often look for

A simple checklist to audit yourself before applying:

Scientific credibility. Can you read a paper, spot a weak control, and explain a mechanism to a non-scientist in two minutes?
Clinical and regulatory literacy. Do you know what an IND, a Phase 2b, a surrogate endpoint, and an accelerated approval are, and how each changes a company's value?
Financial fluency. Can you build a risk-adjusted NPV, a cap table with tranched preferred stock, and a fund-level return case?
Market sizing discipline. Can you estimate prevalence, addressable patients, pricing, and penetration without hand-waving?
Sourcing potential. Do you have live relationships with labs, technology transfer offices, founders, or pharma business development teams?
Judgment under uncertainty. Have you defended a pass as well as a push, with reasons that aged well?
Operating empathy. Have you worked inside a startup or lab team long enough to know what slows science down?
Writing. Are your memos short, structured, and decisive?

How to build the diligence record before you have the job

Here's the catch in breaking in: funds want evidence of investment judgment from people who haven't been allowed to invest yet. Fellowships can cover part of that gap. So can structured training that puts you inside a real process.

1752vc's Venture Fellow program is one structured version of that: 8 weeks of live virtual sessions in which Fellows take live companies through due diligence, work from the pitch materials those companies sent, and write case studies, finishing with a certification. For a scientist or clinician, we think the useful part is often less the curriculum than the reps. That's where you learn the point at which a fund's questions stop being scientific and start being about ownership, milestones and the next financing. Applications are accepted on a rolling basis.

If you remember one thing

Biotech VC rewards people who can hold two kinds of risk in their head at once: will the science work, and will the money work. Show both on paper before you ask for the job.

The lab teaches you what's true.

The fund needs to know what it's worth.

Key takeaways

To get into biotech venture capital you typically need scientific depth plus financial fluency; most junior hires have a PhD or MD and prior consulting, banking, or startup experience.
Value in biotech is created at clinical and regulatory milestones, so rounds are often tranched against them and holds run longer than in software.
PitchBook data reported by BioSpace in February 2026 shows biopharma venture funding of about $33.8 billion across 1,171 deals in 2025, with only 32 percent of the venture share going to early-stage companies.
Venture5's 2025 survey puts median venture base salaries near $130,000 for associates and $200,000 for VPs and principals; those are base figures only.
In our view, a written thesis and a mock investment memo anchored in real phase transition rates are artifacts that can help get you interviews.

Frequently asked questions

Do you need a PhD to get into biotech venture capital?

Not strictly, but it is the most common credential at early-stage and company-creation firms, and MDs are close behind. Later-stage and crossover funds hire healthcare bankers, equity research analysts, and life science consultants without doctorates. What most firms look for is the ability to evaluate science and finance together.

How much do biotech VCs make?

Venture5's 2025 salary survey reports median base salaries of about $130,000 for associates, $200,000 for VPs and principals, and $300,000 for investment partners across venture generally. Mergers & Inquisitions puts total biotech VC associate compensation at roughly $150,000 to $250,000, rising to the $500,000 to $1 million range at senior levels. Fund size and city move these numbers a lot.

How do you get into biotech venture capital?

Most commonly with a PhD or MD combined with a year or two in life science consulting, healthcare banking, or an operating role at a startup. That mix shows you can read the science, model the business, and understand how companies actually get built. Fellowship experience at a venture firm can add the diligence track record many candidates lack.

How is biotech VC different from tech VC?

Biotech firms often create companies in-house, release capital in milestone-based tranches, and value companies on clinical and regulatory progress rather than revenue. Diligence is scientific: trial design, endpoints, competing mechanisms, and manufacturing. Timelines are set by the clinic, so holds tend to be longer and the binary risk of a failed readout is real.

What does scientific due diligence in biotech VC involve?

Reading the primary literature and the company's own data, checking whether the preclinical models actually support the proposed indication, pressure-testing the trial design and endpoints, mapping competing mechanisms, reviewing intellectual property and freedom to operate, and asking outside academic and clinical experts what they would need to see. Many funds pair an internal scientist with paid external advisers.

Sources

Disclaimer: This guide is for general education only and is not legal, tax or investment advice. Laws, market data and program terms change, so it may not reflect the latest developments or fit your situation. Treat it as a starting point, not a source of truth, and talk to a qualified lawyer, accountant or financial adviser before you make decisions.